Candel Therapeutics Files 8-K: Material Agreement and Other Events
Ticker: CADL · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1841387
Sentiment: neutral
Topics: material-agreement, 8-k, filing
TL;DR
Candel Therapeutics signed a big deal and filed an 8-K. Details TBD.
AI Summary
On December 12, 2024, Candel Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits as part of this 8-K filing. Specific details of the agreement and financial information were not provided in the excerpt.
Why It Matters
This filing indicates significant corporate activity for Candel Therapeutics, potentially involving new partnerships, financing, or strategic changes that could impact its business operations and stock.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant opportunities or risks for the company, but the lack of specific details necessitates a medium risk assessment.
Key Players & Entities
- Candel Therapeutics, Inc. (company) — Registrant
- December 12, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Candel Therapeutics?
The provided excerpt does not specify the nature or terms of the material definitive agreement.
What are the 'Other Events' reported by Candel Therapeutics in this 8-K filing?
The excerpt mentions 'Other Events' as an item information but does not provide any details about what these events are.
What financial statements and exhibits are included with this 8-K filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific contents are not detailed in the provided text.
When was Candel Therapeutics, Inc. incorporated and in which state?
Candel Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address and phone number for Candel Therapeutics, Inc.?
The principal executive offices are located at 117 Kendrick St., Suite 450, Needham, MA 02494, and the phone number is (617) 916-5445.
Filing Stats: 1,416 words · 6 min read · ~5 pages · Grade level 11.9 · Accepted 2024-12-13 17:30:31
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share CADL The Nasdaq
- $6.00 — on Stock"), at a price to the public of $6.00 per share, and (b) pre-funded warrants
- $5.99 — Warrants"), at a price to the public of $5.99 per warrant with an exercise price of $
- $74.7 million — ffering expenses, will be approximately $74.7 million (or approximately $86.0 million if the
- $86.0 million — imately $74.7 million (or approximately $86.0 million if the underwriters exercise their opti
Filing Documents
- d859956d8k.htm (8-K) — 36KB
- d859956dex11.htm (EX-1.1) — 199KB
- d859956dex41.htm (EX-4.1) — 67KB
- d859956dex51.htm (EX-5.1) — 9KB
- d859956dex991.htm (EX-99.1) — 10KB
- d859956dex992.htm (EX-99.2) — 10KB
- g859956dsp65.jpg (GRAPHIC) — 7KB
- g859956dsp67a.jpg (GRAPHIC) — 15KB
- g859956dsp69.jpg (GRAPHIC) — 10KB
- 0001193125-24-278717.txt ( ) — 588KB
- cadl-20241212.xsd (EX-101.SCH) — 3KB
- cadl-20241212_lab.xml (EX-101.LAB) — 18KB
- cadl-20241212_pre.xml (EX-101.PRE) — 11KB
- d859956d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement dated December 12, 2024. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of Goodwin Procter LLP. 23.1 Consent of Goodwin Procter LLP (contained in Exhibit 5.1). 99.1 Launch Press Release dated December 12, 2024. 99.2 Pricing Press Release dated December 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that are based on the Company's beliefs and assumptions and on information currently available to the Company on the date of this Current Report. These forward-looking statements involve substantial risks and uncertainties. Any statements in this Current Report on Form 8-K other than statements of historical fact, including statements about the Company's future expectations, plans and prospects, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company's strategy, operations and future expectations and plans and prospects for the Company, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's financial and operating results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including the factors discussed in the "Risk Factors" section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company's views only as of the date of this Current Report on Form 8-K. The Company anticipates that subsequent events and developments may cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law even if new information becomes available in the future.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Candel Therapeutics, Inc. Date: December 13, 2024 By: /s/ Paul Peter Tak Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer